Sanofi beats Q1 sales forecasts, driven by strong Dupixent demand

Sanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflammatory drug, whose sales jumped 31% to €4.2 billion, beating analyst estimates by more than 6%.\n\nThe company reaffirmed its 2026 guidance, projecting a high‑single‑digit percentage increase in sales at constant exchange rates and earnings growth slightly faster than sales.\n\nThe upbeat report arrives as Sanofi prepares for a leadership change, with Belén Garijo set to become CEO after Paul Hudson’s departure, and she has pledged tighter execution of the company’s strategy.